BioSpace News Archive

Our transfer agent is Standard Transfer & Co, and has been our SEC registered agent since our inception in 1996.

Pharma artificial intelligence pioneer tellic today announced the creation of its advisory board to provide external strategic review of and expert advice to the company’s management with regards to drug360 graph, tellic’s new knowledge graph software as a service offering.

This third quarter filing should further assist our existing shareholders and new investors with additional detailed information about Agritek Holdings and our expanded business strategy as we move toward the year end.

As Chairman of InHealth Medical Services, Kim will guide the growth of the company’s clinically proven lifestyle therapeutics to improve health and business outcomes.

Lysogene, a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system diseases, reports its cash position as of 30 September 2019.

Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients in Japan, and for which significant unmet medical need exists

MMS Holdings announced that its regional operations in South Africa has more than doubled in the past fiscal year, through the addition of new colleagues in Bloemfontein and the successful procurement of key contracts with clinical trial sponsors and research groups.

TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced it has raised €38.75 million in a Series B round of funding.

Causaly, the AI company teaching computers to read, understand and interpret biomedical knowledge, is pleased to announce its series A fundraising round, which saw new and existing investors commit $4.8m into the company.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced it has presented data from an ongoing Phase 1/2 clinical trial entitled “A Phase 1/2 Study in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions”